用三类药物向加列-1 诱导口腔状细胞癌中的铁亡
Wei-Tso Chia1,2,3, Cheng-Yu Yang4,5, Wei-Chin Chang4,5
1Department of Orthopedics, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu 302, Taiwan.
Cancers
|March 14, 2026
概括
在口腔状细胞癌 (OSCC) 中,托利德 (TPL) 通过铁死诱导癌细胞死亡,通过减少加列-1 (Gal-1) 表达. 高的Gal-1水平与患者生存率差相关,这表明Gal-1调制是OSCC的治疗标.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 口腔状细胞癌 (OSCC) 存在重大治疗挑战,特别是在晚期,由于治疗耐药性.
- 脂质过氧化引发的细胞死亡途径铁灭,在癌症中提供了潜在的治疗脆弱性.
- 加勒-1 (Gal-1/LGALS1),在OSCC中经常过度表达,与瘤进展和不良预后有关,但其在铁死中的作用尚不清楚.
研究的目的:
- 调查Triptolide (TPL) 是否通过调节 Galectin-1 (Gal-1) 表达方式影响OSCC中的铁化.
- 评估TPL对OSCC细胞活力,脂质活性氧物种 (ROS) 和谷氨过氧酶4 (GPX4) 水平的影响.
- 分析Gal-1表达,患者存活率和TPL体内抗瘤作用之间的相关性.
主要方法:
- 用TPL对待OSCC细胞系 (SAS,HSC-3),以测量细胞活力,脂质ROS和GPX4表达.
- 癌症基因组图谱 (TCGA) 数据库分析了OSCC中的Gal-1表达模式和生存关联.
- 采用OSCC异种移植小鼠模型来评估TPL的抗瘤疗效和铁死标记物变化.
主要成果:
- TPL治疗降低了OSCC细胞活力,增加了脂质ROS,同时降低了GPX4表达的调节.
- 暴露于TPL导致Gal-1表达在体外和体内都减少.
- 在TCGA数据中,高Gal-1表达与OSCC患者的整体存活率较差显著相关.
结论:
- 在OSCC中,TPL诱导与铁化相关的反应,部分是通过对Gal-1的降低调节.
- 在OSCC中,Gal-1可能会影响ferroptosis易受性,代表潜在的治疗点.
- 准Gal-1通路需要进一步研究新的OSCC治疗策略.
相关概念视频
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63


